Back HIV Policy & Advocacy

HIV Policy & Advocacy

AIDS 2014: Criminalization of Sex Work Increases Vulnerability to HIV

Sex workers from more than 30 countries came together this week at the Sex Worker Pre-Conference preceding the 20th International AIDS Conference in Melbourne to consider proposed changes to policy and funding approaches aimed at positioning human rights as critical to the response to HIV/AIDS.

alt

Read more:

AIDS 2014: iPrEx OLE Confirms PrEP Works, but Many Don't Take It [VIDEO]

The open-label extension of the iPrEx study found that Truvada pre-exposure prophylaxis (PrEP) was highly The open-label extension of the iPrEx study found that Truvada pre-exposure prophylaxis (PrEP) was highly effective among gay men who took it regularly to prevent HIV, but many did not do so, researchers reported this week at the 20th International AIDS Conference in Melbourne.

alt

Read more:

AIDS 2014: Romidepsin Activates Latent HIV, But Does Not Decrease Viral Reservoir

The HDAC inhibitor romidepsin was able to awaken latent HIV in resting T-cells, causing it to start producing new virus, but this was not associated with a decrease in the size of the viral reservoir in T-cells, researchers reported at the 20th International AIDS Conference this week in Melbourne. This finding suggests that kicking HIV out of hiding will not be adequate for a functional cure without strengthening immune response against the virus.

alt

Read more:

AIDS 2014: Researchers Discuss Progress Towards an HIV Cure [VIDEO]

Progress along the multi-pronged path towards a cure for HIV was one of the themes at the 20th International AIDS Conference (AIDS 2014), taking place this week in Melbourne. Researchers provided updates on the "Mississippi Baby," a novel assay for detecting low levels of hidden virus in the body, and using the anti-cancer drug romidepsin to reactivate latent virus.

alt

Read more:

AIDS 2014: iPrEx OLE Shows PrEP Effectiveness Is 100% for Those Taking 4 or More Doses per Week

iPrEx OLE, the open-label extension of the iPrEx study of pre-exposure prophylaxis (PrEP), reported its main findings this week at the 20th International AIDS Conference in Melbourne, Australia, published simultaneously in The Lancet Infectious Diseases. Overall PrEP effectiveness was 50% overall, but 100% in those taking 4 or more doses per week. There was a substantial early drop-out rate, especially among young people.

alt

Read more: